January 20, 2015

U.S. Supreme Court Partially Modifies Standard of Review of Patent Claim Construction and Remands Review of Teva's '808 Patent on Copaxone® to Federal Circuit Court of Appeals

PITTSBURGH, Jan. 20, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. Supreme Court has partially modified the standard of review to be applied by the U.S. Court of Appeals for the Federal Circuit when reviewing a lower court's evidentiary findings made when construing a patent claim. Additionally, the Supreme Court has remanded the case relating to Teva's U.S. Patent No. 5,800,808 ("the '808 patent") to the Federal Circuit for that court to review the patent's validity in accordance with the modified standard of review. The '808 patent expires on Sept. 1, 2015.

Mylan CEO Heather Bresch said, "We continue to believe that the '808 patent is invalid as indefinite and we will address that issue with the Federal Circuit Court of Appeals. Nevertheless, Mylan's global platform has consistently demonstrated that our success is not about any one product. With that said, we look forward to bringing our generic version of Copaxone® to market."

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

This press release includes statements that constitute "forward-looking statements," including with regard to litigation and sales of products. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; uncertainties and other matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 25,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com.

Logo - http://photos.prnewswire.com/prnh/20140423/77793

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/us-supreme-court-partially-modifies-standard-of-review-of-patent-claim-construction-and-remands-review-of-tevas-808-patent-on-copaxone-to-federal-circuit-court-of-appeals-300022984.html

SOURCE Mylan Inc.